Sarissa Capital Management LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001577524

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth Tilt how tags are computed

Q3 2023 · 11 positions · Total reported value $742.38M · Top-10 concentration 100.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 10.0% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -11.2% · vs SPY -13.3% · Prev Value $177.88M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -2.3% · vs SPY -4.4% · Latest Value $153.17M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2023 13F filing, Sarissa Capital Management LP disclosed 11 equity positions with a combined reported value of $742.38M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt.

The largest disclosed positions as of Q3 2023 were ALKS ($197.25M), BIIB ($165.26M), IRWD ($157.84M). By sector, the heaviest allocations are Health Care 99.9%, Other 0.1%.

Versus the prior quarter, Sarissa Capital Management LP opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 10.0% of positions.

The largest new positions opened in Q3 2023 were ALKS ($197.25M), BIIB ($165.26M), IRWD ($157.84M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • ALKS ALKERMES PLC · $197.25M
  • BIIB BIOGEN INC · $165.26M
  • IRWD IRONWOOD PHARMACEUTICALS INC · $157.84M
  • INVA INNOVIVA INC · $94.53M
  • GILD GILEAD SCIENCES INC · $68.97M
  • NBIX NEUROCRINE BIOSCIENCES INC · $41.17M
  • AMRN AMARIN CORP PLC · $9.61M
  • BCRX BIOCRYST PHARMACEUTICALS INC · $5.49M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Sarissa Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Sarissa Capital Management LP is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 10 US equity positions with a combined value of $153.17M. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-77926 (status: Approved), registered 2013-04-10
  • Regulatory AUM (Form ADV): $298.34M as of 2026-07-08
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 4 hedge funds

Portfolio Structure

  • 10 positions · $153.17M reported value (Q3 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: INVA (INNOVIVA INC) at 26.2%
  • Average position size: $15.32M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 1 reduced
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 99.9%
Other 0.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 7.04M $197.25M 26.57%
26.57%
New
2 643.00K $165.26M 22.26%
22.26%
New
3 16.39M $157.84M 21.26%
21.26%
New
4 7.28M $94.53M 12.73%
12.73%
New
5 920.40K $68.97M 9.29%
9.29%
New
6 366.00K $41.17M 5.55%
5.55%
New
7 10.44M $9.61M 1.29%
1.29%
New
8 775.00K $5.49M 0.74%
0.74%
New
9 618.00K $1.31M 0.18%
0.18%
New
10 550.00K $698.50K 0.09%
0.09%
New
11 185.18K $253.70K 0.03%
0.03%
New

FAQ

What did Sarissa Capital Management LP buy in 2023-Q3?

In its 2023-Q3 13F filing, Sarissa Capital Management LP reported 11 equity positions worth $742.38M in aggregate; its largest disclosed positions were ALKS ($197.25M), BIIB ($165.26M), IRWD ($157.84M).

How large is Sarissa Capital Management LP's portfolio?

Sarissa Capital Management LP reported $742.38M of long equity holdings across 11 positions as of 2023-Q3. Top-10 holdings account for 100.0% of reported value.

What is Sarissa Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/sarissa-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →